BIO

Aaron Edwards is the CEO and co-founder of KiraGen Bio, a pioneering startup leveraging ML-driven multiplex gene editing to develop CAR-T cells resistant to the immunosuppressive solid tumor microenvironment. Under Aaron’s leadership, KiraGen is working towards offering new hope to patients with aggressive solid tumors worldwide.

Aaron is a soon-to-be graduate with a dual MS/MBA in Biotechnology from Harvard Business School and Harvard Medical School. He also holds an MS in Medical Sciences from Boston University School of Medicine and a BS in Biology from Centre College. During his 4 year tenure at Beam Therapeutics, Aaron served as the in vitro biology lead for BEAM-201, the company’s now-clinical multiplex base edited CAR-T program for pediatric T-ALL. His time at both Beam Therapeutics and bluebird bio before that, coupled with internships at 1910 Genetics, Eli Lilly, Rejuvenate Bio, and BioMarin have deeply enriched his expertise in biotech innovation and business development.

A committed advocate for inclusivity and diversity in the biotech sector, Aaron’s influence extends beyond KiraGen. Outside of work and school, Aaron actively engages with the ‘bioTwitter’ community and is busy raising his goldendoodle puppy named Finn.